Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Immune checkpoint inhibitors (ICIs) show success in advanced non-small-cell lung cancer (NSCLC).
• Their use is expanding to the neoadjuvant setting for early-stage NSCLC.
• Early immune responses to neoadjuvant therapy in NSCLC are not well understood.

Purpose of the Study:

• To investigate the cellular and molecular mechanisms of early immune responses to neoadjuvant therapy in NSCLC.
• To understand the role of the programmed cell death 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) axis in early-stage NSCLC.
• To explore the impact of PD-1 inhibition on tumor growth and the tumor immune microenvironment.

Main Methods:

• Integrated analysis of early-stage NSCLC patients and a Kras mutant mouse model.
• Analysis of intratumoral PD-1+ T cells and PD-L1 expression.
• Assessment of immune microenvironment modulation, T lymphocyte subset depletion, and transcriptome analyses.

Main Results:

• A prevalent PD-1/PD-L1 axis was observed, with increased intratumoral PD-1+ T cells and PD-L1 expression.
• Tumor progression correlated with immune microenvironment changes, showing immunosuppressive phenotypes.
• PD-1 inhibition effectively controlled tumor growth, improved survival, and reprogrammed tumor-associated immune cells.

Conclusions:

• Early targeting of the PD-1/PD-L1 axis is crucial for managing lung cancer progression.
• PD-1 inhibition demonstrates significant therapeutic potential by modulating the immune microenvironment.
• Understanding the temporal dynamics of immune responses informs early intervention strategies in NSCLC.